Aptinyx Inc — Department of Health and Human Services SBIR Phase I: NIA

Description

DESCRIPTION provided by applicant Age related memory loss is a growing public health issue which will be magnified in the coming decades by increasing life expectancies and the aging baby boomer population Age is the most important risk factor for developing dementia of the population between and has some form of dementia between and and of those or older The therapeutic value of cholinesterase inhibitors CIs which are the standard form of treatment for dementia in Alzheimerandapos s disease is modest CIs delay the cognitive decline by only months and their use is limited by cardiovascular contraindications The NMDA receptor is a promising target for addressing age related memory loss Age related decline in NMDAR protein expression and function is observed in humans and other mammals that are directly correlated with memory impairment and performance in learning dependent tasks However most of the known compounds active at the NMDAR produce strong side effects greatly limiting their clinical utility Naurex has developed a novel class of orally bioavailable NMDAR partial agonists based on the companyandapos s NMDAR partial agonist GLYX which has demonstrated exceptional safety and efficacy in clinical trials for depression GLYX and its NRX mimetics improve learning and memory indicators in behavioral assays in rats and enhance long term potentiation in hippocampal slices Importantly they do not produce sedative or psychotomimetic effects The scope of this Phase I project is to identify a lead drug candidate for age related memory loss within the NRX library using advanced models of aging To this end our Specific Aims are SA Perform full dose response curves in both young and learning impaired aged rats evaluating lead orally bioavailable NRX isomers for restoring synaptic plasticity and modulating NMDA receptors in hippocampal slices from young and aging brains SA Use full dose response curves to evaluate the two best compounds screened in SA for the ability to enhance cognitive functioning in normal aging using the Morris water maze task SA Use full dose response curves to evaluate the two best compounds screened in SA for the ability to increase the total number of mature spines in dendrites of hippocampal neurons On its completion the proposed Phase I study will yield a lead molecule that will be advanced to IND enabling studies and subsequent clinical trials for treating age related cognitive decline PUBLIC HEALTH RELEVANCE Age related memory loss is a rising health problem with a broad societal impact while currently available treatment options are inadequate in their efficacy This project will utilize a library of newly developed cognition enhancing small molecules to identify and advance a first in class drug candidate for addressing age related memory decline